Roivant Sciences/$ROIV

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Roivant Sciences

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Ticker

$ROIV
Primary listing

Industry

Biotechnology

Employees

750

ISIN

BMG762791017

Roivant Sciences Metrics

BasicAdvanced
$7.7B
-
-$0.24
1.23
-

What the Analysts think about Roivant Sciences

Analyst ratings (Buy, Hold, Sell) for Roivant Sciences stock.

Bulls say / Bears say

Roivant Sciences' sale of Telavant to Roche for $7.1 billion provides significant capital to invest in its pipeline and strategic initiatives. (thestreet.com)
Analysts have assigned Roivant Sciences an average price target of $17.93, indicating potential upside from current levels. (etfdailynews.com)
Vanguard Group Inc. increased its holdings in Roivant Sciences by 5.8%, reflecting institutional confidence in the company's prospects. (marketbeat.com)
Roivant Sciences' drug for lung disease failed to meet the main goal in a mid-stage trial, raising concerns about its pipeline's robustness. (reuters.com)
The company's Q2 2024 earnings report showed a loss of $0.29 per share, missing analyst expectations and highlighting financial challenges. (zacks.com)
Insider selling, including the COO's sale of 100,000 shares, may signal concerns about the company's future performance. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.

Roivant Sciences Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Roivant Sciences Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ROIV

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs